KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight

KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration

(2015) Sara T. Hjuler et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats

(2014) Kim V. Andreassen et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Prolonged Calcitonin Receptor Signaling by Salmon, but Not Human Calcitonin, Reveals Ligand Bias

(2014) Kim Vietz Andreassen et al.   PLoS One

Amylin Acts in the Central Nervous System to Increase Sympathetic Nerve Activity

(2013) Caroline Fernandes-Santos et al.   ENDOCRINOLOGY

Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide

(2011) C. M. Mack et al.   DIABETES OBESITY & METABOLISM

Enhanced Amylin-Mediated Body Weight Loss in Estradiol-Deficient Diet-Induced Obese Rats

(2010) James L. Trevaskis et al.   ENDOCRINOLOGY

Central amylin acts as an adiposity signal to control body weight and energy expenditure

(2010) Peter Y. Wielinga et al.   PHYSIOLOGY & BEHAVIOR

Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight

(2009) C M Mack et al.   INTERNATIONAL JOURNAL OF OBESITY